These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38481446)

  • 21. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
    Toi M; Imoto S; Ishida T; Ito Y; Iwata H; Masuda N; Mukai H; Saji S; Shimizu A; Ikeda T; Haga H; Saeki T; Aogi K; Sugie T; Ueno T; Kinoshita T; Kai Y; Kitada M; Sato Y; Jimbo K; Sato N; Ishiguro H; Takada M; Ohashi Y; Ohno S
    Lancet Oncol; 2021 Jan; 22(1):74-84. PubMed ID: 33387497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.
    Iwata H
    Breast Cancer; 2011 Apr; 18(2):92-7. PubMed ID: 21140250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant endocrine treatment in primary breast cancer - review of literature.
    Mathew J; Asgeirsson KS; Jackson LR; Cheung KL; Robertson JF
    Breast; 2009 Dec; 18(6):339-44. PubMed ID: 19836953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
    Riemsma R; Forbes CA; Kessels A; Lykopoulos K; Amonkar MM; Rea DW; Kleijnen J
    Breast Cancer Res Treat; 2010 Aug; 123(1):9-24. PubMed ID: 20535542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and meta-analysis.
    Zhang M; Song J; Guo S; Jin F; Zheng A
    Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37283514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.
    Dai Q; Wang Y; Liao M; Chen H
    Ann Palliat Med; 2022 Dec; 11(12):3727-3742. PubMed ID: 36635998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
    Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
    Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
    Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.
    Guarneri V; Griguolo G; Miglietta F; Conte PF; Dieci MV; Girardi F
    ESMO Open; 2022 Apr; 7(2):100433. PubMed ID: 35276440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
    Solinas C; Ceppi M; Lambertini M; Scartozzi M; Buisseret L; Garaud S; Fumagalli D; de Azambuja E; Salgado R; Sotiriou C; Willard-Gallo K; Ignatiadis M
    Cancer Treat Rev; 2017 Jun; 57():8-15. PubMed ID: 28525810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson L; Lawrence D; Dawson C; Bliss J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD003370. PubMed ID: 19821307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.
    Kim HJ; Noh WC; Lee ES; Jung YS; Kim LS; Han W; Nam SJ; Gong G-; Kim HJ; Ahn SH
    Breast Cancer Res; 2020 May; 22(1):54. PubMed ID: 32460816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk-reducing medications for primary breast cancer: a network meta-analysis.
    Mocellin S; Goodwin A; Pasquali S
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012191. PubMed ID: 31032883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
    Kawalec P; Łopuch S; Mikrut A
    Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.
    Sammons S; Sedrak MS; Kimmick GG
    Drugs Aging; 2020 May; 37(5):331-348. PubMed ID: 32100240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.
    Corona SP; Roviello G; Strina C; Milani M; Madaro S; Zanoni D; Allevi G; Aguggini S; Cappelletti MR; Francaviglia M; Azzini C; Cocconi A; Sirico M; Bortul M; Zanconati F; Giudici F; Rosellini P; Meani F; Pagani O; Generali D
    Breast; 2019 Aug; 46():19-24. PubMed ID: 31051411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy.
    Houssami N; Macaskill P; von Minckwitz G; Marinovich ML; Mamounas E
    Eur J Cancer; 2012 Dec; 48(18):3342-54. PubMed ID: 22766518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Utility of Neoadjuvant Endocrine Therapy for Hormone Receptor Positive Breast Cancer.
    Kolberg HC; Aktas B; Liedtke C
    Rev Recent Clin Trials; 2017; 12(2):67-72. PubMed ID: 28155606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
    Robertson JFR; Paridaens RJ; Lichfield J; Bradbury I; Campbell C
    Eur J Cancer; 2021 Mar; 145():19-28. PubMed ID: 33418233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.